{"name":"Ilypsa","slug":"ilypsa","ticker":"","exchange":"","domain":"","description":"Ilypsa is a biotechnology company focused on the development of novel therapies for kidney diseases. The company's lead candidate, ILY101, is currently in Phase 2 clinical trials. Ilypsa aims to address significant unmet medical needs in nephrology through innovative research and development.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNQ2lDb05fTUVhY1hPelBrRTJBb2VmSGgzZGxEdmZBbXpwd1FWdnltOF9xdW9IeEFvODUxZ3h6cFN5R1YzeldodmllNmhnSWZNMUR4Z0dMRDNSX1QzTi1Cd1RNd2NWaWp1NlVVa29zTlVLY0VpZ3pvRFA5Q1BRZ1ozU0FNcDlCMUNxaXM2RGF3eXpjNzBvYUNYVWhn?oc=5","date":"2018-10-21","type":"pipeline","source":"C&EN","summary":"Inside the rarefied world of polymer drug manufacturing - C&EN","headline":"Inside the rarefied world of polymer drug manufacturing - C&EN","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}